|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-10-12
|
|
pubmed:abstractText |
Benign prostatic hyperplasia (BPH) is a common condition in aging men causing lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease progression. Of the different alpha-1 adrenergic receptors (ARs) in the prostate, alpha-1a receptors are known to be central to prostatic smooth-muscle contraction. Recent studies have shown that patients with BPH may also have a predominance of alpha-1d receptors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1469-493X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
CD007360
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
|
|
pubmed:affiliation |
John H. Stroger Hospital of Cook County, Chicago, Illinois, USA, 60607.
|
|
pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis
|
